BioSpace News Archive

4D Molecular Therapeutics, a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, reported first quarter 2024 financial results and provided operational highlights.

AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the execution of an amended agreement with Sagard Healthcare for additional Anaptys Jemperli royalties.

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, provided a business update and reported first quarter 2024 financial results.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, reported financial results for the first quarter ended March 31, 2024.

Allakos Inc., a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, provided a business update and reported financial results for the first quarter ended March 31, 2024.

ALX Oncology Holdings Inc., an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation, announced that it had successfully treated a series of patients delivering therapy in both the left and right atria.

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that an abstract featuring new preclinical data highlighting the therapeutic potential of its StealthX™ exosome platform technology has been selected for an oral presentation at the ASGCT 27th Annual Meeting taking place in Baltimore, Maryland from May 7–11, 2024.

Aqtual, Inc., a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, today announced it is presenting two posters at the Congress of Clinical Rheumatology 2024 meeting in Destin, Florida May 9-12, 2024.

Prometheus Laboratories Inc. announced the execution of provider agreements with three large regional health plans to facilitate access to PredictrPK®, precision-guided biologic testing, and other Prometheus testing services to the participating health plans and their respective members.